Value: A framework for radiation oncology

Journal of Clinical Oncology

Volumn , Issue 26, 2014, Pages 2864-2870

  Teckie, Sewit ^a   McCloskey, Susan A ^b   Steinberg, Michael L ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CONCEPTUAL FRAMEWORK; COST UTILITY ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; MEDICAL CARE; MEDICAL SERVICE; NEOPLASM; ONCOLOGY; OUTCOME ASSESSMENT; PROCESS MONITORING; REVIEW; VALUE BASED HEALTH CARE DELIVERY; ACCOUNTABLE CARE ORGANIZATION; CANCER PATIENT; HEALTH CARE; HEALTH CARE POLICY; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROCEDURES; REIMBURSEMENT; ECONOMICS; NEOPLASMS; STANDARDS;

HEALTH CARE COSTS; HUMANS; NEOPLASMS; RADIATION ONCOLOGY;

EID: 84907016472     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1150     Document Type: Review

References (64)

1. Fuchs VR: The gross domestic product and health care spending. N Engl J Med 369:107-109, 2013
2. Porter ME: A strategy for health care reform: Toward a value-based system. N Engl J Med 361: 109-112, 2009
3. Porter ME, Lee TH: The strategy that will fix health care. Harvard Business Review, October 2013
4. Porter ME: What is value in health care? N Engl J Med 363:2477-2481, 2010
5. Donabedian A: Evaluating the quality of medical care: 1966. Milbank Q 83:691-729, 2005
6. Pauly MV, Burns LR: Price transparency for medical devices. Health Aff (Millwood) 27:1544- 1553, 2008
7. Okike K, O'Toole RV, Pollack AN, et al: Survey finds few orthopedic surgeons know the costs of the devices they implant. Health Aff (Millwood) 33:103-109, 2014
8. Steinberg ML: Introduction: Health policy and health care economics observed. Semin Radiat Oncol 18:149-151, 2008
9. Mitchell JM: Urologists' use of intensitymodulated radiation therapy for prostate cancer. N Engl J Med 369:1629-1637, 2013
10. Mitchell JM: Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection. Health Aff (Millwood) 31:741-749, 2012
11. Hershman DL, Unger JM, Barlow WE, et al: Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology studies S8814/ S8897. J Clin Oncol 27:2157-2162, 2009
12. Gwyn K, Bondy ML, Cohen DS, et al: Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer 100: 1595-1604, 2004
13. Bickell NA, Wang JJ, Oluwole S, et al: Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357-1362, 2006
14. Davidson SM: Open questions concerning influences on clinical decision making. J Ambul Care Manage 36:88-107, 2013
15. He D, Mellor JM: Hospital volume responses to Medicare's Outpatient Prospective Payment System: Evidence from Florida. J Health Econ 31:730- 743, 2012
16. US Government Accountability Office: Higher Use of Costly Prostate Cancer Treatment by Providers Who Self-Refer Warrants Scrutiny. http://www.gao.gov/assets/660/656026.pdf
17. Lohr KN, Brook RH, Kamberg CJ, et al: Use of medical care in the RAND Health Insurance Experiment: Diagnosis- and service-specific analyses in a randomized controlled trial. Med Care 24:S1-S87, 1986 (suppl)
18. Brook RH, Ware JE, Rogers WH, et al: The Effect of Coinsurance on the Health of Adults: Results from the RAND Health Insurance Experiment. Santa Monica, CA, RAND Corporation, 1984
19. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007
20. Keeler EB, Sloss EM, Brook RH, et al: Effects of cost sharing on physiological health, health practices, and worry. Health Serv Res 22:279-306, 1987
21. Chandra A, Gruber J, McKnight R: The impact of patient cost-sharing on low-income populations: Evidence from Massachusetts. J Health Econ 33:57- 66, 2014
22. Moriates C, Shah NT, Arora VM: First, do no (financial) harm. JAMA 310:577-578, 2013
23. Elkin EB, Bach PB: Cancer's next frontier: Addressing high and increasing costs. JAMA 303: 1086-1087, 2010
24. Timmons A, Gooberman-Hill R, Sharp L: "It's at a time in your life when you are most vulnerable": A qualitative exploration of the financial impact of a cancer diagnosis and implications for financial protection in health. PLoS One 8:e77549, 2013
25. Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
26. Wong YN, Egleston BL, Sachdeva K, et al: Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care 51:838-845, 2013
27. Ito K, Elkin E, Blinder V, et al: Costeffectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer 119:2494-2502, 2013
28. Davidoff AJ, Erten M, Schaffer T, et al: Out-ofpocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 119:1257-1265, 2013
29. Ubel PA, Abernethy AP, Zafar SY: Full disclosure: Out-of-pocket costs as side effects. N Engl J Med 369:1484-1486, 2013
30. Alhassani A, Chandra A, Chernew ME: The sources of the SGR "hole." N Engl J Med 366:289- 291, 2012
31. Bogdanich W: Radiation offers new cures, andwaystodoharm.http://www.nytimes.com/2010/ 01/24/health/24radiation.html?-r-0
32. Bogdanich W: As technology surges, radiation safeguards lag. http://www.nytimes.com/2010/01/27/us/27radiation.html?pagewanted-all
33. Boganich W, Rebelo K: A pinpoint beam strays invisibly, harming instead of healing. http://www.nytimes.com/2010/12/29/health/29radiation.html?pagewanted - all
34. Elnahal SM, Kerstiens J, Helsper RS, et al: Proton beam therapy and accountable care: The challenges ahead. Int J Radiat Oncol Biol Phys 85:e165-e172, 2013
35. Lievens Y, Pijls-Johannesma M: Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol 23:134-141, 2013
36. Wallner PE, Steinberg ML, Konski AA: Controversies in the adoption of new healthcare technologies. Front Radiat Ther Oncol 43:60-78, 2011
37. American Society for Radiation Oncology: Safety is No Accident: A Framework for Quality Radiation Oncology and Care. https://www.astro.org/uploadedFiles/Main-Site/Clinical-Practice/Patient-Safety/Blue-Book/SafetyisnoAccident.pdf
38. American Society for Radiation Oncology: Apex: Accreditation program for excellence. https:// www.astro.org/Practice-Management/Practice-Accreditation/Index.aspx
39. American Society of Clinical Oncology: Quality Oncology Practice Initiative (QOPI). http://qopi.asco.org/
40. Klein I, Kolodziej M: Private payers and cancer care: Land of opportunity. J Oncol Pract 10:15-19, 2014
41. Enthoven AC, Crosson FJ, Shortell SM: 'Redefining health care': Medical homes or archipelagos to navigate? Health Aff (Millwood) 26:1366-1372, 2007
42. Steinberg M: Presidential address. https://www.astro.org/uploadedFiles/Main-Site/News-and-Media/ASTROnews/Annual-Meeting-Wrap-Up-2012/astronewsAMwrap-up-2012.pdf
43. Bosserman LD, Verrilli D, McNatt W: Partnering with a payer to develop a value-based medical home pilot: A West Coast practice's experience. J Oncol Pract 8:38s-40s, 2012 (suppl)
44. Birkmeyer JD, Siewers AE, Finlayson EV, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128-1137, 2002
45. Vickers AJ, Bianco FJ, Serio AM, et al: The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 99: 1171-1177, 2007
46. Yim GW, Kim SW, Nam EJ, et al: Learning curve analysis of robot-assisted radical hysterectomy for cervical cancer: Initial experience at a single institution. J Gynecol Oncol 24:303-312, 2013
47. Barrie J, Jayne DG, Wright J, et al: Attaining surgical competency and its implications in surgical clinical trial design: A systematic review of the learning curve in laparoscopic and robot-assisted laparoscopic colorectal cancer surgery. Ann Surg Oncol 21:829-840, 2014
48. Mirheydar HS, Parsons JK: Diffusion of robotics into clinical practice in the United States: Process, patient safety, learning curves, and the public health. World J Urol 31:455-461, 2013
49. Schreuder HW, Wolswijk R, Zweemer RP, et al: Training and learning robotic surgery, time for a more structured approach: A systematic review. BJOG 119:137-149, 2012
50. Zorn KC, Gautam G, Shalhav AL, et al: Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: Recommendations of the society of urologic robotic surgeons. J Urol 182:1126-1132, 2009
51. Marks LB, Light KL, Hubbs JL, et al: The impact of advanced technologies on treatment deviations in radiation treatment delivery. Int J Radiat Oncol Biol Phys 69:1579-1586, 2007
52. Mendenhall WM, Amdur RJ, Palta JR: Intensity-modulated radiotherapy in the standard management of head and neck cancer: Promises and pitfalls. J Clin Oncol 24:2618-2623, 2006
53. Liu HW, Malkoske K, Sasaki D, et al: The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team. Brachytherapy 9:202-207, 2010
54. Fairchild A, Straube W, Laurie F, et al: Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys 87:246-260, 2013
55. Wick EC, Hobson DB, Bennett JL, et al: Implementation of a surgical comprehensive unitbased safety program to reduce surgical site infections. J Am Coll Surg 215:193-200, 2012
56. Arriaga AF, Bader AM, Wong JM, et al: Simulation-based trial of surgical-crisis checklists. N Engl J Med 368:246-253, 2013
57. Valentin A: Approaches to decreasing medication and other care errors in the ICU. Curr Opin Crit Care 19:474-479, 2013
58. Peters LJ, O'Sullivan B, Giralt J, et al: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J Clin Oncol 28:2996-3001, 2010
59. Weber DC, Tomsej M, Melidis C, et al: QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy. Radiother Oncol 105:4-8, 2012
60. Brook RH: The RAND/UCLA Appropriateness Method. Santa Monica, CA, RAND Corporation, 1995
61. Efstathiou JA, Nassif DS, McNutt TR, et al: Practice-based evidence to evidence-based practice: Building the National Radiation Oncology Registry. J Oncol Pract 9:e90-e95, 2013
62. Dodson JA, Reynolds MR, Bao H, et al: Developing a risk model for in-hospital adverse events following ICD implantation: A report from the NCDR® registry. J Am Coll Cardiol [epub ahead of print on November 27, 2013]
63. Basch E, Abernethy AP, Mullins CD, et al: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30:4249-4255, 2012
64. McCloskey SA, Kupelian P, Asch S, et al: Adapting the PRO-CTCAE for patient reporting of toxicity in radiation oncology. Int J Radiat Oncol Biol Phys 84:S99-S100, 2012 (suppl)